Skip to content
Home
  • Contact Us
  • About
    • Our Company
    • Executive Team
    • Board of Directors
    • Scientific Founders
  • Technology
    • Bacteriophage background
    • Phage therapy
    • Biomarker discovery
  • Pipeline
  • Investors
  • Newsroom
  • Publications
  • Careers
  • +972-72-3942377
  • info@biomx.com
  • Connect with us on LinkedIn

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • NYSE: PHGE
    • TASE: PHGE
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Nov 29, 2022 9:10am EST

BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

Nov 09, 2022 6:30am EST

BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 02, 2022 9:00am EDT

BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

Sep 11, 2022 7:22am EDT

BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 10, 2022 6:30am EDT

BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 07, 2022 3:17am EDT

BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022

Aug 04, 2022 11:20am EDT

BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease

Jul 06, 2022 1:45am EDT

BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

Jun 28, 2022 6:30am EDT

Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

Jun 27, 2022 6:30am EDT

BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next
RSS

Investor Contact Information

Company

BiomX, Inc.
22 Einstein St.
Floor 5
Ness Ziona 7414003
Israel
info@biomx.com

Investor Relations

Anat Primovich
Corporate Project Manager
T: +972506977228
anatp@biomx.com

  • Email Alerts
  • Contacts
  • RSS News Feed
  • Advancing Medicine
    Precisely.
  • 2022 © All rights reserved to BiomX
    Terms and Conditions | Privacy Policy

  • UX+UI+Development by Omnis

  • About

    • Our Company
    • Executive Team
    • Board of Directors
    • Scientific Founders
  • Technology

    • Bacteriophage
    • Phage Therapy
    • Biomarker Discovery
  • Pipeline

    • Cystic Fibrosis
    • Atopic Dermatitis
    • IBD/PSC
    • Colorectal cancer
  • Investors

    • OVERVIEW
    • NEWS & EVENTS
    • COMPANY INFO
    • FINANCIAL INFO
    • STOCK DATA
    • SEC FILINGS
    • GOVERNANCE

We use cookies to analyze traffic and continually improve our site.

More info